A new formulation of Pfizer/BioNTech COVID-19 Vaccine "12 years and older, Ready to use (Original/Omicron BA.4-5 Grey Cap and Package, Multi-dose vial) was approved FOR BOOSTER DOSES ONLY on 12/09/22 with procedure II/143.
Additional website content relevant to this new formulation will be available soon

Pfizer-BioNTech COVID-19 Vaccine Original/Omicron BA.4-5 (15/15 micrograms)/ dose dispersion for injection, for 12 years and older, Ready to use (Grey Cap and Package, Multi-dose Vial)


This site is intended for Healthcare Professionals in United Arab Emirates.

TERMS OF USE - Pfizer BioNTech
  1. Use and content of this Web site. The information provided on this site is for general informational and educational purposes and has been approved by relevant regulatory authorities.

    Certain sections of this Web site are intended for Healthcare Professionals only and we ask you to not access these sections if you are not a Healthcare Professional. Specific appropriate sections have been developed and are accessible for the general public. Your access to and use of the information contained in the Web site is subject to this Terms of Use Agreement. By accessing and using this Web site, you accept, without limitation or qualification, this Terms of Use Agreement.
    Neither Pfizer nor any party involved in creating, producing or delivering this Web site shall be liable for any damages, including without limitation, direct, incidental, consequential, indirect or punitive damages, arising out of access to, use of or inability to use this Web site, or any errors or omissions in the content thereof. This limitation includes damages to, or for any viruses that infect, your computer equipment.

  2. Privacy. Pfizer respects the privacy of its Web site users. Please refer to https://privacycenter.pfizer.com/ that explains users' rights and responsibilities with respect to information that is disclosed on this Web site.

  3. Third Party Web sites and Links. This Web site may contain links or references to other Web sites maintained by third parties over whom Pfizer has no control. Such links are provided merely as a convenience. Similarly, this Web site may be accessed from third party links over whom Pfizer has no control. Pfizer makes no warranties or representations of any kind as to the accuracy, currency, or completeness of any information contained in such Web sites and shall have no liability for any damages or injuries of any kind arising from such content or information. Inclusion of any third party link does not imply an endorsement or recommendation by Pfizer.

  4. Medical Information. Patients should not use the information contained in this website for diagnosing a health or fitness problem or disease. Patients should always consult with a doctor or other health care professional for medical advice or information about diagnosis and treatment.

  5. Non-Confidential Information. Subject to any applicable terms and conditions set forth in our Privacy Policy, any communication or other material that you send to us through the Internet or post on a Pfizer Web site by electronic mail or otherwise, such as any questions, comments, suggestions or the like, is and will be deemed to be non-confidential and Pfizer shall have no obligation of any kind with respect to such information. Pfizer shall be free to use any ideas, concepts, know-how or techniques contained in such communication for any purpose whatsoever, including but not limited to, developing, manufacturing and marketing products.

  6. Trademarks. All product names, whether or not appearing in large print or with the trademark symbol, are trademarks of Pfizer, its affiliates, related companies or its licensors or joint venture partners, unless otherwise noted. The use or misuse of these trademarks or any other materials, except as permitted herein, is expressly prohibited and may be in violation of copyright law, trademark law, the law of slander and libel, the law of privacy and publicity, and communications regulations and statutes. Please be advised that Pfizer actively and aggressively enforces its intellectual property rights to the fullest extent of the law.

  7. Copyrights. The entire contents of this Web site are subject to copyright protection. Copyright © 2020 Pfizer Inc. The contents of Pfizer Web sites may not be copied other than for non commercial individual reference with all copyright or other proprietary notices retained, and thereafter may not be recopied, reproduced or otherwise redistributed. Except as expressly provided in the website or above, you may not otherwise copy, display, download, distribute, modify, reproduce, republish or retransmit any information, text or documents contained in this Web site or any portion thereof in any electronic medium or in hard copy, or create any derivative work based on such images, text or documents, without the express written consent of Pfizer. Nothing contained herein shall be construed as conferring by implication, estoppel or otherwise any license or right under any patent or trademark of Pfizer, or any third party.

  8. Void Where Prohibited. This Web site and its contents are intended to comply with the laws and regulations in the E.U. Although the information on this Web site is accessible to users outside of the E.U., the information contained on this website is intended for use only by residents of the E.U. Other countries may have laws, regulatory requirements and medical practices that differ from those in the E.U. Pfizer reserves the right to limit provision of its products or services to any person, geographic region or jurisdiction and/or to limit the quantities or any products or services we provide. Any offer for any product or service made on this Web site is void where prohibited.

  9. Governing Laws. This Terms of Use Agreement and your use of the Web site shall be governed by the laws of Belgium without regard to its conflicts of laws principles. Any legal action or proceeding related to this Web site shall be brought exclusively in a federal or state court of competent jurisdiction sitting in Belgium.

  10. Miscellaneous. If any provision of this Agreement is held to be unlawful, void or unenforceable, then such provision shall be severable without affecting the enforceability of all remaining provisions. Pfizer reserves the right to alter or delete materials from this Web site at any time at its discretion.

For more information ​​​​​​​

Medical Information
Visit PfizerMedicalInformationgulf.com


EUA Fact Sheet Updates

Please be aware that Pfizer-BioNTech COVID-19 Vaccine is now available in three formulations. For additional information on differences across age groups and formulations please see Vaccine Formulations Guide on the home page of this website.

Label Update: Effective 31 AUG 2022

Pfizer-BioNTech COVID-19 Vaccine, Bivalent, which is supplied in a multiple dose vial with an
orange cap and a label with an orange border, should not be used in individuals 12 years of age and older.†

Updated shelf life for
12 years of age and older Dilute Before Use, Purple Cap formulation. Please see the Shelf Life & Storage page of this website for more information. 

Important Safety Information has been updated. Please see the Safety & Efficacy page of this website for details. 

*Monovalent refers to any authorised or approved COVID-19 vaccine that contains or encodes the spike protein of only the Original SARS-CoV-2.

†A different presentation of Pfizer-BioNTech COVID-19 Vaccine, Bivalent supplied in a single dose and multiple dose vials with
gray caps and labels with gray borders is available for use in individuals 12 years of age and older.

Click below to view:
EUA Fact Sheet for Vaccination Providers - 12 year of age and older Dilute Before Use, Purple Cap
 •    EUA Fact Sheet for Vaccination Providers  - 12 years of age and older Do Not Dilute, Bivalent (Original and Omicron BA.4/BA.5), Gray Cap
    •    EUA Fact Sheet for Vaccination Providers - 5 through 11 years of age Dilute Before Use, Orange Cap

For Healthcare Professionals in United Arab Emirates only